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Chronic low back pain (LBP) is a debilitating condition associated with signs of axial and radiating pain. In humans with chronic
LBP, opioids are often prescribed with varying outcomes and a multitude of side eﬀects. Combination therapies, in which multiple
pharmacological agents synergize to ameliorate pain without similar potentiation of adverse reactions, may be useful in improving
therapeutic outcome in these patients. The SPARC-null mouse model of low back pain due to disc degeneration was used to
assess the eﬀects of opioid (morphine) and α2-adrenergic agonist (clonidine) coadministration on measures of axial and radiating
pain. The results indicate that systemic morphine and clonidine, coadministered at a ﬁxed dose of 100:1 (morphine:clonidine),
show a synergistic interaction in reversing signs of axial LBP, in addition to improving the therapeutic window for radiating LBP.
Furthermore, these improvements were observed in the absence of synergy in assays of motor function which are indicative of side
eﬀects such as sedation and motor incoordination. These data show that the addition of low-dose systemic clonidine improves
therapeutic outcome in measures of both axial and radiating pain. Combination therapy could be of enormous beneﬁt to patients
suﬀering from chronic LBP.
1.Introduction
Low back pain (LBP) is a common condition associated
with disability, decrease in quality of life, and signiﬁcant
economic burden [1–3]. Chronic LBP can include both axial
and non-axial symptoms [4]. Axial LBP is characterized by
spontaneous or movement-evoked pain or soreness conﬁned
to the spine and low back region. Radiating, non-axial LBP
is pain that radiates from the back down one or both legs.
This condition is often referred to as radicular pain or
sciatica,becausethepainusuallyfollowsthecourseofthesci-
atic nerve [5–8]. In animal models, radiating pain can be
measuredinthehindpaw.Althoughtheexactmechanismsof
LBP remain unclear, evidence suggests that the degeneration
of intervertebral discs (IVDs) is associated with an increased
risk of chronic LBP [9–12].
Pharmacotherapy is the most common treatment option
for patients suﬀering from LBP with or without radiating
pain [13]. Although non-steroidal anti-inﬂammatory drugs
aretheﬁrstlineofdefenseagainstLBP,theydonotsuﬃcient-
ly treat chronic and severe LBP. Opioids are often prescribed
with varying therapeutic outcome [1, 14, 15]a n da r e
associated with undesired eﬀects that limit their use, such
as constipation, nausea, somnolence, fatigue, and the devel-
opment of tolerance [16]. Since opioids such as morphine
remain the gold standard of chronic pain treatment, it is vital
to investigate strategies that would decrease required doses
without diminishing the therapeutic eﬀects. One such strate-
gy is the addition of a non-opioid analgesic that will poten-
tiate the analgesic eﬀects of morphine without potentiating
the undesirable adverse reactions.2 Pain Research and Treatment
Theadditionofα2-adrenergicagonists(α2ARs)improves
opioid-induced antinociception in rodents following both
systemic and spinal administration [17–25]. Evidence from
human studies suggests that the use of opioid-α2AR agonist
combinations in clinical pain management could minimize
the side eﬀects associated with both α2AR and opioid ther-
apeutics [26, 27]. Furthermore, combination therapy may
be eﬀective in the treatment of chronic, opioid-insensitive
pain states [28], and the α2AR agonist clonidine is approved
for use in chronic pain. To date, the therapeutic beneﬁt of
opioid-α2AR agonist co-administration in chronic axial and
non-axial LBP has not been systematically explored in either
humans or animal models.
In this study, we used the SPARC-null mouse model of
LBP due to disc degeneration (DD) to examine the eﬀects
of opioid-α2AR agonist combinations. SPARC (secreted
protein, acidic, rich in cysteine; aka osteonectin or BM-40) is
anevolutionarilyconservedcollagen-bindingproteinpresent
in IVDs. SPARC is known to inﬂuence bone remodeling, col-
lagenﬁbrillogenesis,andwoundrepair.Decreasedexpression
of SPARC has been associated with aging and DD in human
IVDs [29], and targeted deletion of the SPARC gene results
in accelerateddisc degenerationin the aging mouse [30].DD
inthesemiceisalsoassociatedwithbehaviouralsignsofaxial
and radiating LBP [31, 32].
The aim of the current study is to use the SPARC-null
mouse model of low back pain to study the interaction be-
tween the prototypic opioid (morphine) and alpha-2 adren-
ergic agonists (clonidine) in treating signs of chronic axial
and radiating pain.
Ourresultssupportthehypothesisthatcombinationthe-
rapy using morphine and clonidine has the potential to im-
prove therapeutic outcome for the chronic back pain patient.
2.MaterialsandMethods
2.1. Mice. SPARC-null mice (backcrossed to the C57BL/6
background) and wild-type (WT) controls (C57BL/6, Char-
les River, QC, Canada) were used as in previous studies [31–
34].
4–6 month old male SPARC-null and WT control mice
w e r eb r e di n - h o u s e .A n i m a l sw e r eh o u s e di ng r o u p so f2 –
5, had unrestricted access to food and water, and were on a
12hr light-dark cycle. All drug administration was adjusted
for weight. SPARC-null mice were slightly lighter than WT
mice (SPARC-null: 24.3 ± 0.3 at 4 months and 27.9 ± 0.4a t
6 months; WT: 25.9 ± 0.5 at 4 months and 32.1 ± 0.6a t6
months). All experiments were performed blind to genotype
and treatment, using a randomized block design.
All experiments were approved by the Animal Care
Committee at the McGill University and conformed to the
ethical guidelines of the Canadian Council on Animal Care
andtheguidelinesoftheCommitteeforResearchandEthical
Issues of IASP [35].
2.2. Behavioural Analysis
2.2.1. Tail Suspension Assay. Mice were suspended indivi-
dually underneath a platform by the tail with adhesive tape
attached 0.5 to 1cm from the base of the tail and were
videotaped for 180s. The duration of time spent in (a)
immobility (not moving but stretched out) and (b) escape
behaviours (rearing to reach the underside of the platform,
extending to reach the ﬂoor, or self-supported at the base of
the tail or the suspension tape) were determined. The dura-
tion of immobility reﬂects the animal’s willingness to stretch
its main body axis. Deceased immobility is indicative of
axial discomfort. This test is adapted from a traditional assay
used to measure depression [36], and we have shown that it
reliablymeasuressignsofaxialpaininmice[31,32].Acutoﬀ
of 180 seconds was applied when interpreting the data.
2.2.2. Sensitivity to Cold Stimuli. A modiﬁed version of the
acetone drop test was used [37], where the total duration
of acetone-evoked behaviours (AEBs: ﬂinching, licking, or
biting) were measured in seconds for 1 minute after a drop
of acetone (∼25μL) was applied to the plantar surface of
the hindpaw. An increased behavioural response to acetone
suggests the development of cold allodynia and decreased
reactivityissuggestiveofantiallodynic eﬃcacy.Acutoﬀ of 4s
was applied when interpreting the data to facilitate isobolo-
graphic analysis.
2.2.3.RotarodAssay. Theacceleratingrotarodassaywasused
to monitor animals for motor function (IITC Life Science
Inc., Woodland Hills, CA, USA) with the mouse adapter
(rod diameter, 3.2cm) [38]. The task includes a speed ramp
from 0 to 30 rotations per minute over 60s, followed by an
additional 240s at the maximal speed. A decline in the laten-
cy to fall oﬀ the rotarod reﬂects motor incoordination. Mice
were not trained prior to testing sessions. A cutoﬀ of 200s
was used when interpreting the data.
2.2.4. Open Field Assay. A transparent open ﬁeld apparatus
(24 × 24cm2) was placed in a quiet room illuminated with
white light. The ﬂoor of the apparatus was equally divided
into nine squares (8 × 8cm 2). Mice were individually placed
into the open ﬁeld on the central square, and their spon-
taneous behaviour was videotaped for 5min. Subsequent
analysis of the total number of squares visited was used to
assess general motor activity [39]. An increase in the num-
ber of peripheral squares covered reﬂects hyperactivity, while
a decrease is indicative of sedation. Following drug adminis-
tration, animals underwent tail suspension just before being
placed in the open ﬁeld.
2.2.5. Timeline. The schedule of testing was as follows: 16
weeks of age: habituation to tail suspension; 20 weeks: base-
line open ﬁeld and tail suspension assays; 22 and 26 weeks:
baseline and after drug administration for acetone and
rotarod assays; 24 and 28 weeks: tail suspension and open
ﬁeldafterdrugadministration.Awash-outperiodof2weeks
was included between drug exposures to ensure that only the
acute eﬀects of each drug were studied.
2.3. Pharmacological Treatment. Analgesic agents or saline
control were administered to SPARC-null and WT mice byPain Research and Treatment 3
Table 1: Eﬀect of combination therapy on drug potency.
Assay Strain Morphine ED50 Clonidine ED50
Observed Theoretical
Interaction combination combination
ED50 ED50
Tail suspension (Axial pain) SPARC-null 10 (±4.0) 0.05 (±0.04) 0.08 (±0.23) 3.3 (±2.1) Synergistic
WT 18 (±6.0) 8.2 (±21) NA 17 (±5.7) NA
Acetone (cold allodynia) SPARC-null ∼35 (±50) 0.08 (±0.09) 3.5 (±6.3) 6.6 (±6.0) Additive
WT 6 (±2.0) 0.1 (±0.2) 2.7 (±8.9) 4.2 (±1.8) Additive
Rotarod (motor incoordination) SPARC-null 8 (±6.1) 0.3 (±0.3) ∼56 (±85) 6.5 (±4.5) Additive
WT ∼17 (±14) 0.1(±0.2) No eﬃcacy 7.3 (±7.4) NA
Open ﬁeld (overall activity) SPARC-null ∗0.2 (±0.1) 0.2 (±0.2) No eﬃcacy NA NA
WT ∗0.6 (±0.3) 0.14(± 0.16) ∗0.13 (± 0.08) NA NA
Morphine and clonidine ED50 values (mg/kg, i.p.) either alone or in combination at a dose ratio of 100:1 (observed combination ED50). The Theoretical
Combination ED50 is the predicted ED50 for the combination in the absence of any interaction. The interaction indicates if the observed combination ED50
was statistically diﬀerent from the theoretical combination ED50. ∼ indicates that the ED50 value was determined by extrapolation if maximum eﬃcacy was
lessthan50%. ∗Intheopenﬁeldassay,morphinehadnopotencyasasedativebutcausedhyperactivity.Adrugordrugcombinationwasconsideredtoexhibit
no eﬃcacy if maximum eﬃcacy was under 30%. NA = not available (it is not possible to calculate these values when one drug lacks eﬃcacy).
i.p. injection (5mL/kg injected directly in theintra-peritone-
al cavity). Morphine (Medisca Inc., Montreal, QC, Canada)
and clonidine (Sigma-Aldrich Canada Ltd., Oakville, ON,
Canada) were dissolved in 0.9% saline either alone or
in combination at a constant dose ratio of 100:1 (mor-
phine:clonidine). Animals were tested 60 minutes after drug
administration.
2.4. Data Analysis
2.4.1. Behavioural Phenotype of LBP. Comparisons between
saline-treated SPARC-null and WT mice were performed for
eachassayby2-tailed,unpairedt-test.Welch’scorrectionwas
used when the condition of equal variances was not met.
Sample size ranged between 35 and 48 mice/group of saline-
treated mice.
2.4.2. Dose-Response Analysis (Table 1). Individual dose
points are reported as raw data for both strains and all phar-
macological treatments as means with standard error of the
mean (SEM). In order to calculate ED50 values, individual
dose points were ﬁrst converted to % maximum possible
eﬀect (%MPE) according to the following equations
Tail suspension:
%M P E=
drug −saline
maximum − saline
×100,
maximum eﬀect = 180 seconds in immobility.
(1)
Acetone:
%M P E=
saline − drug
saline −maximum
×100,
maximum eﬀect = 0 seconds of AEB-induced behaviour.
(2)
Rotarod:
%M P E=
saline −drug
saline −maximum
×100,
maximum eﬀect = 0 seconds latency to fall.
(3)
Open ﬁeld:
%M P E=
saline −drug
saline −maximum
×100,
maximum eﬀect = 0 squares crossed.
(4)
ED50 values and conﬁdence limits were calculated
according to the graded dose-response method of Tallarida
and Murray [40] on the linear portion of each dose-response
curve.ED50 valuesweredetermined byextrapolationincases
where maximum eﬃcacy was between 30 and 50%. If 30%
eﬃcacywasnotreached,ED50 valueswerenotcalculatedand
was considered to lack eﬃcacy. A minimum of three doses
were used for each drug or combination of drugs.
2.4.3. Isobolographic Analysis (Table 1). Isobolographic anal-
ysis is the “gold standard” for evaluating drug interactions
[40, 41]. Dose-response curves were constructed for each
agonist administered alone, and the ED50 values were calcu-
lated. The two drugs were then coadministered at a constant
dose-ratio approximately equal to their potency ratio, a third
dose-response curve was constructed, and an experimentally
derived combination ED50 was calculated.
To test for interactions between agonists, the ED50 values
and standard error of all dose-response curves were arithme-
t i c a l l ya r r a n g e da r o u n dt h eE D 50 value using the following
equation: (ln(10)×ED50)×(SEM of log ED50)[ 41]. Isobo-
lographic analysis necessitates this manipulation. When test-
ing an interaction between two drugs, a theoretical additive
ED50 value is calculated for the combination based on the
dose-response curves of each drug administered separately.
This theoretical value is then compared by a t-test with the
observed experimental ED50 value of the combination. An
interaction is considered synergistic if the experimental ED504 Pain Research and Treatment
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Figure 1: Morphine and clonidine synergize to attenuate axial pain in SPARC-null mice. (a) Saline-treated SPARC-null animals spend less
timeinimmobilitycomparedtoWTmiceinthetailsuspensionassay,indicativeofaxialpain.(b),(b )InSPARC-nullmice(b),morphine(•)
and clonidine () dose-dependently inhibited axial pain when administered systemically either alone or coadministered (i.p.) at a constant
dose ratio of 100:1 (morphine:clonidine). In WT mice (b ), morphine (•) and clonidine () dose-dependently inhibited axial pain when
administeredsystemically,butthecombinationlackedeﬃcacy.(c)Isobolographicanalysisappliedtothedatafrom(b).The y-axisrepresents
the ED50 for morphine, and the x-axis represents the ED50 for clonidine. The lines directed from each ED50 v a l u et o w a r dz e r oa r et h el o w e r
95% conﬁdence limits of each ED50. The line connecting these two points is the theoretical additive line. The open circle on the theoretical
additive line represents the calculated theoretical ED50 value of the combination if the interaction is additive. The observed combination
ED50 (•) was signiﬁcantly (P<0.05; t-test) lower than the theoretical additive ED50 (◦), indicating that the interaction is synergistic. An
isobolograph was not plotted for WT mice, since the combination lacked eﬃcacy in this assay. Error bars represent ±SEM for each dose
point (n = 5–11 animals/dose). See Table 1 for ED50 values. ∗∗∗P<0.0001.
is signiﬁcantly less (P<0.05) than the calculated theoretical
additive ED50.
Visualization of drug interactions can be facilitated and
enhanced by graphical representation of isobolographic ana-
lysis (Figures 1, 2,a n d3,c – c  ). This representation depicts
the ED50 of each agent on the x-o ry-axis. For example,
Figure 1(c) presents the ED50 of morphine on the y-axis and
theED50 ofclonidineonthex-axis.Thelineconnectingthese
two points depicts the dose combinations expected to yield
50% eﬃcacy if the interaction is purely additive and is called
the theoretical additive line. The theoretical additive ED50
and its conﬁdence interval are determined mathematically
and plotted spanning this line. The observed ED50 for the
combination is plotted at the corresponding x, y coordinates
along with its 95% conﬁdence interval for comparison to the
theoretical additive ED50. Isobolographs were plotted only
whenbothdrugsaloneandthecombinationshowedeﬃcacy.
All dose-response and isobolographic analyses were per-
formed with the FlashCalc pharmacological statistics soft-
ware package generously supplied by Dr. Michael Ossipov.
2.4.4. Therapeutic Window (Table 2). Therapeutic window
(TW) is a measure of the amount of an agent required to
produce the desired eﬀect (i.e., analgesia) compared to the
amount that produces the undesired eﬀect (i.e., motor im-
pairment).InthisstudywedeﬁnetheTWastheED50 (unde-
sired eﬀect)/ED50 (desired eﬀect). A TW < 1 indicates the
drug is more potent in the production of the undesired eﬀectPain Research and Treatment 5
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Figure 2: Eﬀect of coadministration of morphine and clonidine on cold allodynia. (a) Saline-treated SPARC-null animals exhibit more
acetone-evoked behaviours compared to WT mice in the acetone assay, indicative of cold hypersensitivity on the hindpaw. (b), (b ). In
both SPARC-null (b) and WT (b ) mice, morphine (•) and clonidine () dose-dependently inhibited cold allodynia when administered
systemically either alone or coadministered (i.p.) at a constant dose ratio of 100:1 (morphine:clonidine). (c), (c ) Isobolographic analysis
applied to the data from (b), (b ). The y-axis represents the ED50 for morphine, and the x- a x i sr e p r e s e n t st h eE D 50 for clonidine. The lines
directed from each ED50 value toward zero represent the respective lower 95% conﬁdence limits of each ED50. The line connecting these two
points is the theoretical additive line. The open circle on the theoretical additive line represents the calculated theoretical ED50 value of the
combination if the interaction is additive. The observed combination ED50 (•) was not signiﬁcantly diﬀerent (t-test) from the theoretical
additive ED50 (◦) in either strain, indicating that the interaction is additive in both cases. Error bars represent ±SEM for each dose point (n
= 5–11 animals/dose). See Table 1 for ED50 values. ∗∗∗P<0.0001.
than the desired eﬀect. A TW > 1 indicates that the desired
eﬀect can be achieved in the absence of the side eﬀect. High-
er indices are more advantageous therapeutically.
3. Results
3.1. Morphine and Clonidine Synergize to Improve Axial Pain
in the Tail Suspension Assay. SPARC-null mice show signs
of axial pain compared to WT mice as shown in the tail
suspension assay (135.4 ± 5.2sinWTversus86.8 ± 5.7sin
SPARC-null, P<0.0001, 2-tailed t-test, Figure 1(a)). Both in
SPARC-null and WT mice, systemic administration of either
morphine or clonidine produced dose-dependent increases
in immobility, indicative of reduced axial discomfort, 60
minutes after injection (Figures 1(b), 1(b )).
The dose-response data from Figure 1(b) is represented
graphically as an isobologram in Figure 1(c). As shown in
Figure 1(c), the ED50 of the combination (closed circle) in
SPARC-null mice is lower than the theoretical additive ED50
(open circle), indicating that this interaction is synergistic.
This synergistic interaction was conﬁrmed by statistical
comparison between the observed combined ED50 value and
the theoretical additive ED50 value.
In WT mice, all morphine + clonidine coadminis-
tration doses showed similar eﬃcacy in the range tested
(Figure 1(b )). Additional doses of this combination need
to be explored to resolve the dose-response relationship
necessary for isobolographic analysis (Table 1).
3.2. Morphine and Clonidine Are Additive in the Acetone
Test of Cold Allodynia. SPARC-null mice show signs of cold6 Pain Research and Treatment
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Figure 3: Eﬀect of coadministration of morphine and clonidine on motor function. (a) Saline-treated SPARC-null animals perform better
on the rotarod assay compared to WT mice, indicative of an absence of motor impairment in SPARC-null mice. (b), (b ) In SPARC-null
mice (b), morphine (•) and clonidine () dose-dependently caused motor impairment when administered systemically either alone or
coadministered (i.p.) at a constant dose ratio of 100:1 (morphine:clonidine). In WT mice (b ), morphine (•) and clonidine ()d o s e -
dependently caused motor incoordination when administered systemically, but the combination lacked eﬃcacy. (c) Isobolographic analysis
applied to the data from Figure 1(b). The y-axis represents the ED50 for morphine, and the x-axis represents the ED50 for clonidine. The
lines directed from each ED50 value toward zero represent the respective lower 95% conﬁdence limits of each ED50. The line connecting
these two points is the theoretical additive line. The open circle on the theoretical additive line represents the calculated theoretical ED50
value of the combination if the interaction is additive. The observed combination ED50 (•) was not signiﬁcantly diﬀerent (t-test) from the
theoretical additive ED50 (◦), indicating that the interaction is additive. Isobolographic analysis was not performed in WT mice since the
combination lacked eﬃcacy in this assay. Error bars represent ±SEM for each dose point (n = 5–11animals/dose). See Table 1 for ED50
values. ∗∗∗P<0.0001.
allodynia on the hindpaw compared to WT mice, as shown
in the acetone assay (1.2 ± 0.1s in WT versus 2.6 ± 0.2s
in SPARC-null, P<0.0001, 2-tailed t-test, Figure 2(a)).
In SPARC-null mice, systemic administration of clonidine
produced dose-dependent analgesia in the acetone assay at
60 minutes after injection, while morphine failed to reach
50% MPE but was of suﬃcient maximum eﬃcacy (45%) to
extrapolate an ED50 value (Figure 2(b)).
In WT mice, the administration of either morphine or
clonidine alone produced dose-dependent antinociception
in the acetone assay (Figure 2(b )). This interaction was
tested statistically by comparing the observed combined
ED50 value and the theoretical additive ED50 value and was
shown to be additive. The dose-response data from Figures
2(b), 2(b ) are represented graphically as isobolograms in
Figures 2(c), 2(c ). As shown in Figures 2(c), 2(c ), the
ED50 of the combination (closed circle) in both strains is
not signiﬁcantly diﬀerent from the theoretical additive ED50
(open circle), indicating that this interaction is additive
(Table 1).
3.3. Morphine and Clonidine Are Additive in the Rotarod
Test of Motor Impairment. SPARC-null mice do not show
signs of motor impairment at 6 months of age. Rather, they
perform better than WT mice in the rotarod assay at thisPain Research and Treatment 7
Table 2: Combination therapy improves therapeutic window.
Strain Drug(s) ED50 value (±SE; mg/kg, i.p.) Therapeutic window
Motor Axial Non-axial Motor/axial Motor/non-axial
SPARC-null
Morphine 8 (±6.1) 10 (±4.0) ∼35 (±50) 0.8 0.2
Clonidine 0.3 (±0.3) 0.05 (±0.04) 0.08 (±0.09) 6.8 4.3
Morphine (+ CLON; 100:1) ∼56 (±85) 0.08 (±0.23) 3.5 (±6.3) 700 16
WT
Morphine ∼17 (±14) 18 (±6.0) 6.0 (±2.0) 0.9 2.8
Clonidine 0.1 (±0.2) 8.2 (±21) 0.1 (±0.2) 0.01 1.0
Morphine (+ CLON; 100:1) No eﬃcacy No eﬃcacy 2.7 (±8.9) N/A N/A
The Therapeutic window is the ratio of the ED50 value (mg/kg, i.p.) of the undesired eﬀect (motor impairment) to the desired eﬀect (inhibition of axial or
non-axial pain). A larger therapeutic window suggests the drug or drug combination will be analgesic at doses that do not produce motor impairment. ∼
indicates that the ED50 value was determined by extrapolation if maximum eﬃcacy was less than 50%. NA = not available (the combination lacked eﬃcacy in
the rotarod assay in WT mice). Note the much larger therapeutic window achieved with the addition of clonidine to morphine.
age (92.1 ± 5.9s in WT versus 136.2 ± 6.2 s in SPARC-
null, P<0.0001, 2-tailed t-test, Figure 3(a)). In SPARC-
null mice, systemic administration of either morphine or
clonidine produced dose-dependent motor impairment in
the rotarod assay at 60 minutes after injection (Figure 3(b)).
Only clonidine produced a dose-dependent eﬀect in WTs
(Figure 3(b )).
The SPARC-null dose-response data from Figure 3(b) is
represented graphically as an isobologram in Figure 3(c). As
shown in Figure 3(c), the ED50 of the combination (closed
circle) is not signiﬁcantly diﬀerent from the theoretical
additive ED50 (open circle), indicating that this interaction is
additive. In WT mice, morphine + clonidine coadministra-
tion lacked eﬃcacy, and thus it was not possible to perform
isobolographic analysis in this assay (Table 1).
3.4. Opposing Eﬀects of Morphine and Clonidine in the Open
Field Test of Voluntary Activity. SPARC-null mice do not
diﬀer from WTs in the number of peripheral squares covered
in the open ﬁeld, indicative of no overall change motor
activity (49.1 ± 5.9s q u a r e si nW Tv e r s u s4 5 .7 ± 3.8s q u a r e s
in SPARC-null, P = 0.6, 2-tailed t-test, Figure 4(a)). In both
SPARC-null and WT mice, systemic administration of mor-
phine produced dose-dependent hyperactivity, while cloni-
dine produced dose-dependent sedation in the open ﬁeld
assay at 60 minutes after injection in (Figure 4(b), 4(b )).
Since the two agonists exert opposite eﬀects on overall acti-
vity, isobolographic analysis was not performed for the open
ﬁeld test.
3.5. Eﬀect of Morphine and Clonidine Coadministration on
Therapeutic Window. The data presented above demonstrate
that coadministration of morphine and clonidine produces
antinociceptive but not sedative synergy following i.p.
administration. We therefore examined the impact of coad-
ministrationonthetherapeuticwindow(TW)betweenseda-
tion and antinociception. In Table 2, the TW has been cal-
culated for morphine and clonidine alone and in combina-
tion following systemic administration for both axial pain
andcoldallodynia.InSPARC-nullmice,thewindowforeach
drug given alone ranged from 0.2 and 6.8, indicating little
separation between the antinociceptive and sedative eﬀective
dose ranges. In contrast, the addition of a small amount
of clonidine to morphine increased these values to 700 for
axial LBP and 16 for non-axial LBP. These changes reﬂect the
fact that analgesia is reached before sedation when the drugs
are coadministered. These increases in therapeutic window
are the result of potentiation in the antinociceptive assays
in parallel with an additive interaction in the undesired side
eﬀect (motor impairment).
4. Discussion
4 . 1 .M o r p h i n ea n dC l o n i d i n eS y n e r g yI m p r o v e sT h e r a p e u t i c
Outcome for Axial Pain. SPARC-null mice develop behavi-
oural signs of axial pain by 4–6 months of age concurrent
with disc degeneration [31, 32, 42]. In the current study, we
show that while morphine and clonidine dose-dependently
attenuate axial pain, the side eﬀects of motor impairment,
sedation (clonidine), and hyperactivity (morphine) develop
in a similar dose range. Systemic coadministration of mor-
phine and clonidine not only resulted in synergy in SPARC-
null but also the therapeutic window of the combination
was greater than for either drug administered alone. The
pharmacological eﬀects observed in SPARC-null animals are
not likely due to motor impairment or sedation, since the
morphine + clonidine combination lacked eﬃcacy in our
tests of motor function. Furthermore, while morphine pro-
duced increases in overall activity, morphine-treated animals
spent more time in immobility in the tail suspension assay,
indicative of antinociception.
The majority of preclinical studies examining opioid-
α2A Ri n t e r a c t i o n st od a t eh a v eb e e nc a r r i e do u ti nn a ¨ ıve
rodents, where the measured endpoint is antinociception
to cutaneous noxious stimuli [21–25, 43] or inhibition of
chemically-evoked behaviours [44, 45]. In contrast, the cur-
rent study focused on pharmacological reversal of patholog-
ical signs of axial LBP in a preclinical model of intervertebral
disc degeneration-related pain. To our knowledge this is the
ﬁrst demonstration of an opioid-adrenergic antinociceptive
synergy in LBP in preclinical studies.
In patients suﬀering from axial LBP, pain management
remains inadequate. Patients with mild or severe LBP are
oftenprescribedtwoormoremedications inaddition toopi-
oids, reﬂecting the challenging nature of LBP [46]. Currently
the primary use of clonidine as a pain management tool is as8 Pain Research and Treatment
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Figure 4:Eﬀectofcoadministration ofmorphineand clonidine onoverall activity. (a)Saline-treated SPARC-nullanimalsdonotdiﬀer from
WT mice in the number of peripheral squares covered in the open ﬁeld, indicative of comparable overall activity between the two strains.
(b), (b ). Both in SPARC-null (b) and WT (b ) mice, morphine (•) caused an increase in activity, while clonidine () dose-dependently
caused sedation. When coadministered (i.p.) at a constant dose ratio of 100:1 (morphine:clonidine), the combination showed no eﬃcacy
in SPARC-null mice and produced hyperactivity in WT mice. No isobolographs were plotted for either strain as the drugs had opposing
eﬀects. Error bars represent ±SEM for each dose point (n = 5–11animals/dose). See Table 1 for ED50 values.
a spinal adjuvant for opioids in intractable cancer pain [47].
Although not currently indicated for patients with chronic
axialLBP,ourresultssuggestthatlowdosesofsystemiccloni-
dine may be a useful addition to opioid therapy.
4.2.CoadministrationofMorphineandClonidineIncreasesthe
Therapeutic Window for Radiating Pain. Cold allodynia in
the hindpaw of SPARC-null mice is a behavioural measure
of non-axial, radiating pain. While cold allodynia is revers-
ed by systemic clonidine, that eﬃcacy is associated with side
eﬀects including motor impairment and sedation. Although
the coadministration of morphine and clonidine was ad-
ditive in our model, we did observe an improvement in
the therapeutic window, such that therapeutic eﬀects were
observed at doses associated with minimal side eﬀects. We
therefore believe that suppression of cold allodynia by the
combination of morphine and clonidine is independent of
motor impairment.
Radiating pain, which may accompany axial pain in pa-
tients suﬀering from LBP [5–8], is thought to have a mainly
neuropathic mechanism [48]. As a result, anti-neuropathic
agents and not opioids are the treatment of choice in these
patients. Consistent with the reduced opioid eﬃcacy com-
monly associated with neuropathic pain conditions, mor-
phine failed to reach 50% eﬃcacy in cold hypersensitivity in
SPARC-null mice in the current study. Furthermore, while
the ED50 values for morphine were between 8 and 10mg/kg
in the tail suspension and rotarod assays, the extrapolatedPain Research and Treatment 9
ED50 value for morphine in non-axial pain was >30mg/kg.
These observations support the predictive validity of the
current model.
Studies evaluating opioid-α2AR agonist interactions in
rodentmodelsofneuropathicpainhavedemonstratedsyner-
gistic interactions between morphine and the α2AR agonists
clonidineandmoxonidine[17,49].Whilemorphineandclo-
nidinecoadministrationdidnotresultinsynergyinradiating
pain in the current study, it did improve the therapeutic
window in this modality. Previous work demonstrating that
opioid-α2ARsynergyissensitivetobothrouteofadministra-
tion and the behavioral endpoint could explain this seeming
discrepancy [22], as could the use of chronic pain models
with diﬀerent etiologies.
These results, together with the synergy observed in axial
analgesia, demonstrate that combinations of morphine and
clonidine target both the axial and radiating pain aspects ob-
served in SPARC-null mice. In humans, the ability to obtain
suﬃcient relief of both axial and radiating pain with the
combination of morphine and a low dose of clonidine could
result in less adverse drug reactions, fewer undesired or
unanticipated drug interactions, increased patient compli-
ance, and improved quality of life.
4.3. Opioid-α2AR Agonist Interactions. In humans, only a
few studies have examined the interaction between opioid-
α2AR agonists in chronic pain conditions. In one study, the
addition of epidural clonidine beneﬁted patients with intra-
ctable cancer pain, particularly those with a signiﬁcant neu-
ropathic component [47], and the combination of intrathe-
cal morphine + clonidine is useful for the management of
chronic pain after spinal cord injury [50, 51]. In order to
maximize the clinical relevance of the current study, systemic
administration was selected; spinal delivery requires invasive
proceduresthataddadditionalrisks.Avarietyofsystemically
delivered adrenergic agonists (i.e., clonidine, dexmedetomi-
dine, moxonidine, tizanidine) are currently available for use
in humans and could be utilized as adjuvants in patients not
receiving suﬃcient eﬃcacy from opioids.
Although there are many studies reporting functional
interactions between opioids and α2AR agonists (for review
see [52]), the molecular mechanisms underlying these inter-
actionsarenotclear.Dependingontheagonistsused,analge-
sic synergy may be mediated by α2A-, α2B-, or α2C-adrenergic
receptorsubtypesandmu-ordelta-opioidreceptors[44,53–
55]. Evidence from immunohistochemical studies suggests
that opioid receptors are coexpressed in the same population
of sensory neurons as α2ARs [56] and that antinociceptive
synergy requires activation of calcium channels [57, 58]a n d
protein kinase C [45, 59]. Physical association between G
protein-coupled receptors such as the opioid and adrenergic
receptors has been proposed to account for the synergistic
eﬀects observed [56, 60, 61]. It is well established that coex-
pression of GPCRs results in the formation of heteromeric
complexes with altered functional and ligand binding prop-
erties [62]. Such interactions could occur at the level of the
primary aﬀerent neurons, the spinal cord and other sites
in the CNS (i.e., locus coeruleus [63]), as well as in the
periphery.
5. FutureDirections
We have studied the acute eﬀects of morphine, clonidine,
and their combination 60 minutes after systemic administra-
tion. However, in clinical situations most patients undergo
chronic pharmacotherapy. It is therefore critical to study
these interactions using a chronic dosing paradigm. The use
of multimodal therapy may be of even greater therapeutic
beneﬁt if chronic studies reveal protective eﬀects of the
combinationagainstthedevelopmentoftoleranceoropioid-
induced hyperalgesia.Clonidine is also known to reduce opi-
oid withdrawal symptoms, a property that may be beneﬁcial
in long-term management of chronic noncancer pain [64].
Our study was carried out in a transgenic mouse model
of LBP due to disc degeneration. While this model incor-
porates pharmacologically reversible behavioral measures of
both axial and radiating pain associated with progressive,
age-dependent intervertebral disc degeneration [31, 32,
42], it is unlikely to fully parallel patients suﬀering from
LBP. Ultimately further studies in both preclinical models
and human subjects are required to fully understand the
therapeutic beneﬁt of adrenergic adjuvant therapy.
6. Conclusions
We have used a mouse model of chronic LBP due to pro-
gressive disc degeneration to explore the eﬀects of morphine
and clonidine coadministration on measures of axial and
radiating pain. Side eﬀects including motor impairment and
overall change in activity were also assessed. This is the ﬁrst
study to report a synergistic interaction between clinically
used analgesics in a rodent model of chronic low back pain
and to include the measurement of both axial and radiating
pain. The results indicate that the addition of low-dose
systemic clonidine can improve therapeutic outcomes both
in axial and radiating pain measures, which could be of
enormous beneﬁt to patients suﬀering from chronic LBP.
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